{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:56:07Z","timestamp":1783032967577,"version":"3.54.6"},"reference-count":120,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bcp.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T14:14:43Z","timestamp":1437920083000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["AChR-specific immunosuppressive therapy of myasthenia gravis"],"prefix":"10.1016","volume":"97","author":[{"given":"Jie","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2015.07.011_bib0005","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"Drachman","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","article-title":"Acetylcholine receptors and myasthenia","volume":"23","author":"Lindstrom","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2015.07.011_bib0020","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2015.07.011_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.bcp.2015.07.011_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2004-829593","article-title":"The epidemiology of myasthenia gravis","volume":"24","author":"Phillips","year":"2004","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0035","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0040","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ana.23791","article-title":"Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis","volume":"73","author":"Cufi","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0050","doi-asserted-by":"crossref","first-page":"404053","DOI":"10.1155\/2013\/404053","article-title":"Recent advances in genetic predisposition of myasthenia gravis","volume":"2013","author":"Zagoriti","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bcp.2015.07.011_bib0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bcp.2015.07.011_bib0060","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0065","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2015.07.011_bib0070","doi-asserted-by":"crossref","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","article-title":"Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients","volume":"9","author":"Kordas","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2015.07.011_bib0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0080","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ana.410160502","article-title":"Myasthenia gravis and myasthenic syndromes","volume":"16","author":"Engel","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0085","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0090","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0095","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0100","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.bcp.2015.07.011_bib0105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/icvts\/ivt510","article-title":"Is thymectomy in non-thymomatous myasthenia gravis of any benefit","volume":"18","author":"Diaz","year":"2014","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"10.1016\/j.bcp.2015.07.011_bib0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1196\/annals.1405.014","article-title":"Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone","volume":"1132","author":"Newsom-Davis","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0115","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"10.1016\/j.bcp.2015.07.011_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.17925\/ENR.2010.05.02.95","article-title":"The role of rituximab in the treatment of myasthenia gravis","volume":"5","author":"Benveniste","year":"2010","journal-title":"Eur. Neurol. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0140","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/1756285608093888","article-title":"Progress in the treatment of myasthenia gravis","volume":"1","author":"Gold","year":"2008","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.bcp.2015.07.011_bib0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S1474-4422(03)00264-3","article-title":"Immunotherapy in autoimmune neuromuscular disorders","volume":"2","author":"Gold","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nm.2625","article-title":"Optimization of current and future therapy for autoimmune diseases","volume":"18","author":"Steinman","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0155","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ana.22025","article-title":"Zero tolerance (to acetylcholine receptor) and ways to overcome it","volume":"67","author":"Wekerle","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0160","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1084\/jem.141.6.1365","article-title":"Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs","volume":"141","author":"Lennon","year":"1975","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0165","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1084\/jem.144.3.726","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0170","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/08916934.2011.622015","article-title":"Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors","volume":"45","author":"Luo","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.bcp.2015.07.011_bib0175","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/256128a0","article-title":"Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor","volume":"256","author":"Tarrab-Hazdai","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2015.07.011_bib0180","first-page":"13","article-title":"Induction of experimental myasthenia gravis in rhesus monkeys: a model for the study of the human disease","volume":"5","author":"Toro-Goyco","year":"1986","journal-title":"P. R. Health Sci. J."},{"key":"10.1016\/j.bcp.2015.07.011_bib0185","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1034\/j.1600-065x.2001.1840111.x","article-title":"Rat models as tool to develop new immunotherapies","volume":"184","author":"Link","year":"2001","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0190","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1749-6632.1976.tb47691.x","article-title":"Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects","volume":"274","author":"Lindstrom","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-5728(87)90092-0","article-title":"Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor","volume":"15","author":"Tzartos","year":"1987","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0200","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.1179220","article-title":"Myasthenia gravis: passive transfer from man to mouse","volume":"190","author":"Toyka","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.bcp.2015.07.011_bib0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJM197701202960301","article-title":"Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice","volume":"296","author":"Toyka","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0210","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bcp.2015.07.011_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60261-8","article-title":"Autoimmune response to acetylcholine receptors in myasthenia gravis and its animal model","volume":"27","author":"Lindstrom","year":"1979","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0220","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0225","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0230","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0014-5793(83)80688-7","article-title":"Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor","volume":"158","author":"Tzartos","year":"1983","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2015.07.011_bib0235","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1152\/physrev.00015.2011","article-title":"End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease","volume":"92","author":"Sine","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0240","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1021\/bi00520a016","article-title":"Identification of exposed and buried determinants of the membrane-bound acetylcholine receptor from Torpedo californica","volume":"20","author":"Froehner","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2015.07.011_bib0245","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0896-6273(95)90037-3","article-title":"Three-dimensional location of the main immunogenic region of the acetylcholine receptor","volume":"15","author":"Beroukhim","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.bcp.2015.07.011_bib0250","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/35077011","article-title":"Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors","volume":"411","author":"Brejc","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2015.07.011_bib0255","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jmb.2004.12.031","article-title":"Refined structure of the nicotinic acetylcholine receptor at 4\u00c5 resolution","volume":"346","author":"Unwin","year":"2005","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0260","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-5793(90)80286-R","article-title":"Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis","volume":"267","author":"Saedi","year":"1990","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bcp.2015.07.011_bib0270","doi-asserted-by":"crossref","first-page":"21642","DOI":"10.1016\/S0021-9258(18)45789-4","article-title":"TE671 cells express an abundance of a partially mature acetylcholine receptor \u03b1 subunit which has characteristics of an assembly intermediate","volume":"265","author":"Conroy","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2015.07.011_bib0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.2012.06766.x","article-title":"Myasthenogenicity of the main immunogenic region","volume":"1274","author":"Lindstrom","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0285","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00005072-197609000-00008","article-title":"Experimental autoimmune myasthenia gravis: a sequential and quantitative study of the neuromuscular junction ultrastructure and electrophysiologic correlations","volume":"35","author":"Engel","year":"1976","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0290","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1749-6632.1976.tb47676.x","article-title":"The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study","volume":"274","author":"Engel","year":"1976","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0300","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0165-5728(03)00209-1","article-title":"Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis","volume":"140","author":"Feferman","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1471-4159.2009.06439.x","article-title":"The loop between \u03b2-strands \u03b22 and \u03b23 and its interaction with the N-terminal \u03b1-helix is essential for biogenesis of \u03b17 nicotinic receptors","volume":"112","author":"Criado","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bcp.2015.07.011_bib0315","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1073\/pnas.75.8.4006","article-title":"Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor","volume":"75","author":"Bartfeld","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0320","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0165-5728(94)00187-S","article-title":"Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor","volume":"58","author":"Ma","year":"1995","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0325","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.410360504","article-title":"Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis","volume":"36","author":"Okumura","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0165-5728(93)90045-Z","article-title":"Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor","volume":"44","author":"Wang","year":"1993","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0335","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-2249.1998.00521.x","article-title":"Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals","volume":"111","author":"Shi","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0340","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1046\/j.1365-2249.1997.4701367.x","article-title":"Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG)","volume":"109","author":"Loutrari","year":"1997","journal-title":"Clin. Exp. Immunol"},{"key":"10.1016\/j.bcp.2015.07.011_bib0345","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1073\/pnas.96.14.8086","article-title":"Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor \u03b1-subunit","volume":"96","author":"Barchan","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2014.06.003","article-title":"Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches","volume":"54","author":"Fuchs","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2015.07.011_bib0355","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1172\/JCI8121","article-title":"Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment","volume":"104","author":"Im","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.07.011_bib0360","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0165-5728(00)00395-7","article-title":"Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis","volume":"111","author":"Im","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0365","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jneuroim.2004.04.010","article-title":"Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment","volume":"152","author":"Maiti","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0370","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.4049\/jimmunol.165.7.3599","article-title":"Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis","volume":"165","author":"Im","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0375","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.molimm.2008.08.264","article-title":"Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor","volume":"46","author":"Yi","year":"2008","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0380","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.1998.tb10910.x","article-title":"Molecular and antigenic structure of nicotinic acetylcholine receptors","volume":"841","author":"Lindstrom","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0385","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0167-5699(93)90237-F","article-title":"Myasthenia gravis: recognition of a human autoantigen at the molecular level","volume":"14","author":"Protti","year":"1993","journal-title":"Immunol. Today"},{"key":"10.1016\/j.bcp.2015.07.011_bib0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1196\/annals.1405.007","article-title":"Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains","volume":"1132","author":"Lindstrom","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0395","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/ana.21901","article-title":"Specific immunotherapy of experimental myasthenia gravis by a novel mechanism","volume":"67","author":"Luo","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0400","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1073\/pnas.89.13.5852","article-title":"Epitope-specific suppression of antibody response in experimental autoimmune myasthenia gravis by a monomethoxypolyethylene glycol conjugate of a myasthenogenic synthetic peptide","volume":"89","author":"Atassi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0405","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI7121","article-title":"Oral administration of an immunodominant T-cell epitope downregulates Th1\/Th2 cytokines and prevents experimental myasthenia gravis","volume":"104","author":"Baggi","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.07.011_bib0410","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1172\/JCI119857","article-title":"Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences","volume":"100","author":"Karachunski","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2015.07.011_bib0415","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0165-5728(98)00208-2","article-title":"Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis","volume":"93","author":"Karachunski","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0420","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/clin.1993.1030","article-title":"Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region \u03b1 146-162 of acetylcholine receptor","volume":"66","author":"Shenoy","year":"1993","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0425","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.4049\/jimmunol.159.6.3016","article-title":"Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis","volume":"159","author":"Wu","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0430","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0167-5699(96)10022-0","article-title":"Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting","volume":"17","author":"Hawke","year":"1996","journal-title":"Immunol. Today"},{"key":"10.1016\/j.bcp.2015.07.011_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06832.x","article-title":"Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future","volume":"1274","author":"Dalakas","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0440","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","article-title":"Antigen-specific immunotherapy of autoimmune and allergic diseases","volume":"22","author":"Sabatos-Peyton","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0445","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.274.5293.1707","article-title":"Induction of autoimmune diabetes by oral administration of autoantigen","volume":"274","author":"Blanas","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.bcp.2015.07.011_bib0450","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/clin.1997.4432","article-title":"Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases","volume":"85","author":"Xiao","year":"1997","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0455","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.146.7.2245","article-title":"Recombinant human acetylcholine receptor \u03b1-subunit induces chronic experimental autoimmune myasthenia gravis","volume":"146","author":"Lennon","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0460","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1073\/pnas.75.2.769","article-title":"Immunization of rats with polypeptide chains from Torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle","volume":"75","author":"Lindstrom","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2015.07.011_bib0465","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.autrev.2013.03.006","article-title":"Novel future therapeutic options in myasthenia gravis","volume":"12","author":"Dalakas","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0470","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0475","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/intimm\/dxg049","article-title":"Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with \u03b2-amyloid","volume":"15","author":"Cribbs","year":"2003","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0480","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1084\/jem.125.6.1119","article-title":"The effect of passively administered antibody on antibody synthesis","volume":"125","author":"Dixon","year":"1967","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2015.07.011_bib0485","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MOH.0b013e32833199ed","article-title":"Mechanisms of anti-d action in the prevention of hemolytic disease of the fetus and newborn: what can we learn from rodent models","volume":"16","author":"Brinc","year":"2009","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0490","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.18.1.709","article-title":"Regulation of antibody responses via antibodies, complement, and Fc receptors","volume":"18","author":"Heyman","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0495","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jtbi.2006.01.019","article-title":"Mathematical modeling of humoral immune response suppression by passively administered antibodies in mice","volume":"241","author":"Na","year":"2006","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0500","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0505","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ni1440","article-title":"Fc\u03b3RIIb controls bone marrow plasma cell persistence and apoptosis","volume":"8","author":"Xiang","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0510","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","article-title":"Functional diversity of helper T lymphocytes","volume":"383","author":"Abbas","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2015.07.011_bib0515","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.4049\/jimmunol.1100796","article-title":"Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice","volume":"187","author":"Hammers","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0520","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0525","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.autrev.2011.05.004","article-title":"Human FoxP3+ regulatory T cells in systemic autoimmune diseases","volume":"10","author":"Miyara","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0530","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2015.03.008","article-title":"Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity","volume":"281","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0535","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","article-title":"Functional defect of regulatory CD4+CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis","volume":"105","author":"Balandina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2015.07.011_bib0540","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2567.2005.02220.x","article-title":"Circulating and thymic CD4+CD25+ T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment","volume":"116","author":"Fattorossi","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2015.07.011_bib0545","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","article-title":"Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: Roles of IL-17 and TNF-\u03b1","volume":"52","author":"Gradolatto","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.bcp.2015.07.011_bib0550","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clim.2007.10.001","article-title":"Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis","volume":"126","author":"Li","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0555","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4049\/jimmunol.0802046","article-title":"Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients","volume":"183","author":"Luther","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0560","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4+CD25highCD127low\/\u2212 T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0565","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.4049\/jimmunol.180.4.2132","article-title":"Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis","volume":"180","author":"Aricha","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0570","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.autrev.2013.03.009","article-title":"Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model","volume":"12","author":"Gertel-Lapter","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bcp.2015.07.011_bib0575","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17402520600876804","article-title":"Oral tolerance: therapeutic implications for autoimmune diseases","volume":"13","author":"Faria","year":"2006","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0580","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.4049\/jimmunol.1002942","article-title":"Foxp3+ regulatory T cells control humoral autoimmunity by suppressing the development of long-lived plasma cells","volume":"186","author":"Jang","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0585","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1471-4906(02)02288-3","article-title":"Pathogen-specific regulatory T cells provoke a shift in the Th1\/Th2 paradigm in immunity to infectious diseases","volume":"23","author":"McGuirk","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0590","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.3390\/ijms16023307","article-title":"Significant roles of regulatory T cells and myeloid derived suppressor cells in hepatitis B virus persistent infection and hepatitis B virus-related HCCs","volume":"16","author":"Kondo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2015.07.011_bib0595","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nri2510","article-title":"Towards an understanding of the adjuvant action of aluminium","volume":"9","author":"Marrack","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2015.07.011_bib0600","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J. Neurosci."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295215003810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T14:32:49Z","timestamp":1691850769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295215003810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0006295215003810"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.011","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AChR-specific immunosuppressive therapy of myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}